Drugs, hERG and sudden death.

A M Brown

Journal: Cell calcium 2004;35(6):543-7

PMID: 15110144

Full Text on Elsevier Science View on PubMed

Abstract

Early recognition of potential QT/TdP liability is now an essential component of the drug discovery/drug development program. The hERG assay is an indispensable step and a high-quality assay must accompany any investigational new drug (IND) application. While it is the gold standard at present, the hERG assay is too labor-intensive and too low throughput to be used as a screen early in the discovery/development process. A variety of indirect high throughput screens have been used.

Address: MetroHealth Campus, Case Western Rreserve University, Cleveland, OH 44128, USA. [email protected]

DOI: 10.1016/j.ceca.2004.01.008

Link outs

Free resources

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0143...

MeSH Terms: Death, Sudden, Cardiac, Drug Evaluation, Preclinical, ERG1 Potassium Channel, Ether-A-Go-Go Potassium Channels, Humans, Long QT Syndrome, Potassium Channels, Potassium Channels, Voltage-Gated, Terfenadine